Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam R Glassman

Showing results (81-90 of 127) with videos related to

Pageof 13
Sort By:
JAMA Ophthalmology|October 23, 2018
Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic RetinopathyLloyd Paul Aiello, Isoken Odia, Adam R Glassman, et al.
JAMA Ophthalmology|April 28, 2017
Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and RanibizumabSusan B Bressler, Danni Liu, Adam R Glassman, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|March 11, 2009
Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema, Roy W Beck, Allison R Edwards, et al.
Ophthalmology Science|June 17, 2024
Visual Function Measurements in Eyes With Diabetic Retinopathy: An Expert Opinion on Available MeasuresAdam R Glassman, Mohamed Ashraf Elmasry, Darrell E Baskin, et al.
JAMA Ophthalmology|May 6, 2021
Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical TrialAdam R Glassman, Wesley T Beaulieu, Maureen G Maguire, et al.
JAMA Ophthalmology|February 21, 2020
Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical TrialAdam R Glassman, Carl W Baker, Wesley T Beaulieu, et al.
Retina (Philadelphia, Pa.)|November 15, 2017
PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical TrialLee M Jampol, Isoken Odia, Adam R Glassman, et al.
Ophthalmology|May 14, 2020
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)Adam R Glassman, John A Wells, Kristin Josic, et al.
American Journal of Ophthalmology|January 24, 2016
Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular EdemaSusan B Bressler, Adam R Glassman, Talat Almukhtar, et al.
Retina (Philadelphia, Pa.)|October 1, 2019
ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR Retina Network Randomized Clinical TrialsNeil M Bressler, Wesley T Beaulieu, Susan B Bressler, et al.
Pageof 13

Showing results (81-90 of 127) with videos related to

Sort By:
Pageof 13
JAMA Ophthalmology|October 23, 2018
Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic RetinopathyLloyd Paul Aiello, Isoken Odia, Adam R Glassman, et al.
JAMA Ophthalmology|April 28, 2017
Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and RanibizumabSusan B Bressler, Danni Liu, Adam R Glassman, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|March 11, 2009
Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema, Roy W Beck, Allison R Edwards, et al.
Ophthalmology Science|June 17, 2024
Visual Function Measurements in Eyes With Diabetic Retinopathy: An Expert Opinion on Available MeasuresAdam R Glassman, Mohamed Ashraf Elmasry, Darrell E Baskin, et al.
JAMA Ophthalmology|May 6, 2021
Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical TrialAdam R Glassman, Wesley T Beaulieu, Maureen G Maguire, et al.
JAMA Ophthalmology|February 21, 2020
Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical TrialAdam R Glassman, Carl W Baker, Wesley T Beaulieu, et al.
Retina (Philadelphia, Pa.)|November 15, 2017
PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical TrialLee M Jampol, Isoken Odia, Adam R Glassman, et al.
Ophthalmology|May 14, 2020
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)Adam R Glassman, John A Wells, Kristin Josic, et al.
American Journal of Ophthalmology|January 24, 2016
Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular EdemaSusan B Bressler, Adam R Glassman, Talat Almukhtar, et al.
Retina (Philadelphia, Pa.)|October 1, 2019
ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR Retina Network Randomized Clinical TrialsNeil M Bressler, Wesley T Beaulieu, Susan B Bressler, et al.
Pageof 13